Neurotech International Ltd. · ASX:NTI
Neurotech International — Shareholder Meeting (November 2024)
17 slides from Neurotech International's shareholder meeting presentation, Nov 20, 2024
Slide 1: 2024 AGM Chairman Address and Investor Presentation
ASX Announcement 20 November 2024 2024 AGM Chairman Address and Investor Presentation Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, herein provides the Chai
Slide 2: Chairman Address (continued)
In April, Neurotech announced the appointment of Mr Robert Maxwell Johnston as a Non-Executive Director. Prior to his non-executive director career, Mr Johnston held the position of President and Chief Executive officer of Johnson and Johnson Pacific, a division of the world’s largest healthcare com
Slide 3: Further Information / About Neurotech
Further Information Dr Thomas Duthy Executive Director [email protected] +61 (0)402 493 727 About Neurotech Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has comple
Slide 4: Improving Lives - 2024 Annual General Meeting
For personal use only Improving Lives Investor Presentation Dr Tom Duthy Executive Director 2024 Annual General Meeting 20 November 2024
Slide 5: Disclaimer
Disclaimer For personal use only IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any presentation, any question and answer session a
Slide 6: Neurotech Four Core Strategies
Neurotech Four Core Strategies For personal use only Focus On Rare Focus on Paediatric Patients Neurological Disorders with Neuroinflammation Focus on Partnering Focus On Drug Product with Key Opinion Development Leaders / Clinicians 3
Slide 7: Therapeutic Agent: NTI164
Therapeutic Agent: NTI164 Entourage Effect (led by CBDA, cannabinoids work better together) For personal use only Neuroprotective (protects neurons from damage, promotes regeneration) How does it work? Anti- Neuroinflammatory (sig. reduces inflammation that causes neuronal damage) High potency, Broa
Slide 8: NTI164 – Ideal Target Product Profile
NTI164 – Ideal Target Product Profile For personal use only Prescription Only Medicine FDA, EMA, TGA Approved Multiple Paediatric Neurological Disorders Premium Pricing Reflecting Clinical Investment Reimbursed Orphan Designations + Other Regulatory Levers 1. Based on 73m children with 1/15,700 livi
Slide 9: Clinical Pipeline – 2024
Clinical Pipeline – 2024 Pre-Clinical Phase I/II Phase II/III For personal use only Other Licensed Strains NTI164 NTI164 Cerebral Palsy ASD (NTIASD2) Synthetic Cannabinoid(s) NTI164 combinations PANDAS / PANS1 NTI164 ASD2 (NTIASD1) World-first clinical trials, and first (90 week+ open label extensio
Slide 10: Autism | Rett | PANDAS/PANS
Autism │ Rett │ PANDAS/PANS “The goals of treatment for Autism are to improve core deficits in social communication and social interactions and minimize the impact of restricted behaviours, with an overarching goal to help children develop greater functional skills and independence.” 1 For personal
Slide 11: Intellectual Property – 2024
Intellectual Property – 2024 Other IP & Barriers to Entry For personal use only Vertically Integrated: Seed to Patient Controlled (Trade Secret: continuity of production to SOP, extraction(s)) Orphan Drug Designation(s) 10 Years Market Exclusivity from Approval – Europe 7 Years Market Exclusivity fr
Slide 12: Clinical Trials, Treatment Durations
Clinical Trials, Treatment Durations All patients can continue on NTI164 ‘extension’ – additional long-term safety and efficacy collected For personal use only 8 weeks 12 weeks 20 weeks 1 Year 2 Years NTI164 Autism (Phase I/II) Rett Syndrome (Phase I/II) PANDAS/PANS (Phase I/II) Autism (Phase II/III
Slide 13: NTI164 Efficacy is Strong, Durable and Consistent
NT1164 Efficacy is Strong, Durable and Consistent Autism (Phase II/III) Rett PANDAS/PANS For personal use only 56% Improvement in Severity of illness at 12 weeks 100% of patients improved by week 20 38% Improvement in Severity of illness at 52 weeks 46% Patients much Improved / improved at 8 weeks 5
Slide 14: 2024 Corporate Strategy
2024 Corporate Strategy For personal use only Secure one or more strategic partnerships for NTI164 in the United States, Europe and certain Asian territories to support clinical, regulatory development, manufacturing and future market launches Global Partnering In 2023, at least 49 deals were announ
Slide 15: 2024 Corporate Strategy: Market Estimates
2024 Corporate Strategy For personal use only Rett Syndrome: 380 pts │ threshold to pay N/A │ Market N/A Australian Market PANDAS/PANS: 1000 pts │ threshold to pay $100k│ Market $100m ASD: 169k pts │ threshold to pay $35.3k│ Market $5.9Bn1 Rett Syndrome: 9,500 pts │ threshold to pay US$0.36m2│ Marke
Slide 16: Key Milestones – NTI164
Key Milestones – NTI164 1H CY2024 2H CY2024 For personal use only • HREC/TGA Approval Cerebral Palsy Phase I/II Clinical Trial • Appointment of A/Prof Carolyn Ellaway as CMO • 24-week PANDAS/PANS Phase I/II Clinical Trial Data • Filing of Orphan Drug Designation USA – PANDAS/PANS + Rett Syndrome • R
Slide 17: Contact Details
For personal use only Contact Details Dr Tom Duthy Executive Director [email protected] +61 402 493 727 *This presentation has been authorised by the Board of Neurotech International Limited www.neurotechinternational.com Neurotech International Limited (ASX: NTI) 14
Neurotech International — Shareholder Meeting (November 2024) on 6ix